(RTTNews) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the potential risk of Guillain-Barré Syndrome following ...
Hosted on MSN1y
GSK’s Arexvy label expansion will intensify competition with Pfizer’s Abrysvo in RSV spaceGSK’s vaccine Arexvy is currently undergoing regulatory review with the potential of being approved in Europe for use in adults aged between 50 and 59 who are at an increased risk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback